On the formation and nature of the imidazoline I2 binding site on human monoamine oxidase-B

Pharmacological Research

Volumn 62, Issue 6, 2010, Pages 475-488

  McDonald, G Reid ^a   Olivieri, Aldo ^a   Ramsay, Rona R ^b   Holt, Andrew ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

2 BFI; Enzyme kinetics; Imidazoline I2 site; Monoamine oxidase B; Phenylethylamine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; IMIDAZOLINE I2 RECEPTOR; MONOAMINE OXIDASE B INHIBITOR; PHENETHYLAMINE; RADIOLIGAND; TRANYLCYPROMINE;

ARTICLE; BINDING AFFINITY; BINDING SITE; CATALYSIS; CONTROLLED STUDY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME KINETICS; ENZYME MECHANISM; ENZYME METABOLISM; ENZYME SUBSTRATE; HUMAN; INCUBATION TIME; LIGAND BINDING; NONHUMAN; OXIDATION; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; BENZOFURANS; BINDING SITES; HUMANS; IMIDAZOLES; IMIDAZOLINE RECEPTORS; LIGANDS; MODELS, MOLECULAR; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; MUTATION; PHENETHYLAMINES; PROTEIN BINDING; RECOMBINANT PROTEINS; TRANYLCYPROMINE;

EID: 78049526876     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2010.09.001     Document Type: Article

References (41)

1. Renouard A., Widdowson P.S., Cordi A. [3H]-idazoxan binding to rabbit cerebral cortex recognises multiple imidazoline I2-type receptors: pharmacological characterization and relationship to monoamine oxidase. Br J Pharmacol 1993, 109:625-631.
2. Sastre M., Garcia-Sevilla J.A. Opposite age-dependent changes of alpha 2A-adrenoceptors and nonadrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) in the human brain: strong correlation of I2 with monoamine oxidase-B sites. J Neurochem 1993, 61:881-889.
3. Tesson F., Limon-Boulez I., Urban P., Puype M., Vandekerckhove J., Coupry I., et al. Localization of I2-imidazoline binding sites on monoamine oxidases. J Biol Chem 1995, 270:9856-9861.
4. Alemany R., Olmos G., Garcia-Sevilla J.A. Labelling of I2B-imidazoline receptors by [3H]2-(2-benzofuranyl)-2-imidazoline (2-BFI) in rat brain and liver: characterization, regulation and relation to monoamine oxidase enzymes. Naunyn Schmiedebergs Arch Pharmacol 1997, 356:39-47.
5. Raddatz R., Parini A., Lanier S.M. Localization of the imidazoline binding domain on monoamine oxidase B. Mol Pharmacol 1997, 52:549-553.
6. Steinberg M.I., Wiest S.A., Pickard R.T., Chen K., Shih J.C. Binding of the imidazoline ligand 3H-2-benzofuranyl-2-imidazoline (BFI) to human brain and platelets. Potentiation by tranylcypromine and role of MAO isoforms. Ann NY Acad Sci 1999, 881:193-198.
7. Carpéné C., Collon P., Remaury A., Cordi A., Hudson A., Nutt D., et al. Inhibition of amine oxidase activity by derivatives that recognize imidazoline I2 sites. J Pharmacol Exp Ther 1995, 272:681-688.
8. Ozaita A., Olmos G., Boronat M.A., Lizcano J.M., Unzeta M., Garcia-Sevilla J.A. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver. Br J Pharmacol 1997, 121:901-912.
9. Jones T.Z., Giurato L., Guccione S., Ramsay R.R. Interactions of imidazoline ligands with the active site of purified monoamine oxidase A. FEBS J 2007, 274:1567-1575.
10. Wiest S.A., Steinberg M.I. 3H[2-(2-benzofuranyl)-2-imidazoline] (BFI) binding in human platelets: modulation by tranylcypromine. Naunyn Schmiedebergs Arch Pharmacol 1999, 360:209-216.
11. Raddatz R., Savic S.L., Bakthavachalam V., Lesnick J., Jasper J.R., McGrath C.R., et al. Imidazoline-binding domains on monoamine oxidase B and subpopulations of enzyme. J Pharmacol Exp Ther 2000, 292:1135-1145.
12. Edmondson D.E., Binda C., Wang J., Upadhyay A.K., Mattevi A. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. Biochemistry 2009, 48:4220-4230.
13. Binda C., Li M., Hubálek F., Restelli N., Edmondson D.E., Mattevi A. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. PNAS 2003, 100:9750-9755.
14. Binda C., Newton-Vinson P., Hubálek F., Edmondson D.E., Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nature Struct Biol 2002, 9:22-26.
15. Hudson A.L., Chapleo C.B., Lewis J.W., Husbands S., Grivas K., Mallard N.J., et al. Identification of ligands selective for central I2-imidazoline binding sites. Neurochem Int 1997, 30:47-53.
16. Kinemuchi H., Arai Y., Oreland L., Tipton K.F., Fowler C.J. Time-dependent inhibition of monoamine oxidase by β-phenethylamine. Biochem Pharmacol 1982, 31:959-964.
17. Newton-Vinson P., Hubálek F., Edmondson D.E. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif 2000, 20:334-345.
18. Holt A., Smith D.J., Cendron L., Zanotti G., Rigo A., Di Paolo M.L. Multiple binding sites for substrates and modulators of semicarbazide-sensitive amine oxidases: kinetic consequences. Mol Pharmacol 2008, 73:525-538.
19. Holt A., Palcic M.M. A peroxidase-coupled continuous absorbance plate-reader assay for flavin monoamine oxidases, copper-containing amine oxidases and related enzymes. Nat Protocols 2006, 1:2498-2505.
20. McDonald G.R., Hudson A.L., Dunn S.M., You H., Baker G.B., Whittal R., et al. Bioactive contaminants leach from disposable laboratory plasticware. Science 2008, 322:917.
21. Bonivento D., Milczek E.M., McDonald G.R., Binda C., Holt A., Edmondson D.E., et al. Potentiation of ligand binding through cooperative effects in monoamine oxidase B. J Biol Chem 2010, (in press). 10.1074/jbc.M110.169482.
22. De Vos H., Bricca G., De Keyser J., De Backer J.P., Bousquet P., Vauquelin G. Imidazoline receptors, non-adrenergic idazoxan binding sites and alpha 2-adrenoceptors in the human central nervous system. Neuroscience 1994, 59:589-598.
23. Hubálek F., Binda C., Khalil A., Li M., Mattevi A., Castagnoli N., et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem 2005, 280:15761-15766.
24. Ramsay R.R., Sablin S.O., Bachurin S.O., Singer T.P. Oxidation of tetrahydrostilbazole by monoamine oxidase A demonstrates the effect of alternate pathways in the kinetic mechanism. Biochemistry 1993, 32:9025-9030.
25. Houslay M.D., Tipton K.F. The reaction pathway of membrane-bound rat liver mitochondrial monoamine oxidase. Biochem J 1973, 135:735-750.
26. Pearce L.B., Roth J.A. Human brain monoamine oxidase type B: mechanism of deamination as probed by steady-state methods. Biochemistry 1985, 24:1821-1826.
27. Tan A.K., Ramsay R.R. Substrate-specific enhancement of the oxidative half-reaction of monoamine oxidase. Biochemistry 1993, 32:2137-2143.
28. Ramsay R.R., Koerber S.C., Singer T.P. Stopped-flow studies on the mechanism of oxidation of N-methyl-4-phenyltetrahydropyridine by bovine liver monoamine oxidase B. Biochemistry 1987, 26:3045-3050.
29. Kachalova G.S., Bourenkov G.P., Mengesdorf T., Schenk S., Maun H.R., Burghammer M., et al. Crystal structure analysis of free and substrate-bound 6-hydroxy-L-nicotine oxidase from Arthrobacter nicotinovorans. J Mol Biol 2010, 396:785-799.
30. Husain M., Edmondson D.E., Singer T.P. Kinetic studies on the catalytic mechanism of liver monoamine oxidase. Biochemistry 1982, 21:595-600.
31. Hynson R.M., Kelly S.M., Price N.C., Ramsay R.R. Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophys Acta 2004, 1672:60-66.
32. Segel I.H. Enzyme kinetics. Behavior and analysis of rapid equilibrium and steady-state enzyme systems 1993, John Wiley & Sons, Inc., New York.
33. Cheng Y., Prusoff W.H. Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973, 22:3099-3108.
34. Binda C., Wang J., Li M., Hubálek F., Mattevi A., Edmondson D.E. Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B. Biochemistry 2008, 47:5616-5625.
35. Ghisla S., Massey V., Choong Y.S. Covalent adducts of lactate oxidase. Photochemical formation and structure identification. J Biol Chem 1979, 254:10662-10669.
36. Maycock A.L., Abeles R.H., Salach J.I., Singer T.P. The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase. Biochemistry 1976, 15:114-125.
37. Wiest S.A., Steinberg M.I. Binding of [3H]2-(2-benzofuranyl)-2-imidazoline (BFI) to human brain: potentiation by tranylcypromine. Life Sci 1997, 60:605-615.
38. Meana J.J., Barturen F., Martin I., Garcia-Sevilla J.A. Evidence of increased non-adrenoceptor [3H]idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol Psychiatry 1993, 34:498-501.
39. Ruiz J., Martin I., Callado L.F., Meana J.J., Barturen F., Garcia-Sevilla J.A. Non-adrenoceptor [3H]idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci Lett 1993, 160:109-112.
40. Brown C.M., MacKinnon A.C., Redfern W.S., Williams A., Linton C., Stewart M., et al. RS-45041-190: a selective, high-affinity ligand for I2 imidazoline receptors. Br J Pharmacol 1995, 116:1737-1744.
41. Remaury A., Raddatz R., Ordener C., Savic S., Shih J.C., Chen K., et al. Analysis of the pharmacological and molecular heterogeneity of I(2)-imidazoline-binding proteins using monoamine oxidase-deficient mouse models. Mol Pharmacol 2000, 58:1085-1090.